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Background: The cellular form of the prion protein (PrPC) is implicated in Alzheimer disease as a receptor for amyloid-
(A).
Results: An assay was developed capable of identifying inhibitors of A binding to PrPC.
Conclusion: Chicago Sky Blue inhibits A binding to PrPC.
Significance: This is the first small molecule shown to disrupt the binding of A to PrPC.
The prion protein (PrP) has been implicated both in prion
diseases such as Creutzfeldt-Jakob disease, where its mono-
meric cellular isoform (PrPC) is recruited into pathogenic self-
propagating polymers of misfolded protein, and in Alzheimer
disease, where PrPC may act as a receptor for synaptotoxic olig-
omeric forms of amyloid- (A). There has been considerable
interest in identification of compounds that bind to PrPC, stabi-
lizing its native fold and thereby acting as pharmacological
chaperones to block prion propagation and pathogenesis. How-
ever, compounds binding PrPC could also inhibit the binding of
toxic A species and may have a role in treating Alzheimer dis-
ease, a highly prevalent dementia for which there are currently
no disease-modifying treatments. However, the absence of a
unitary, readily measurable, physiological function of PrP
makes screening for ligands challenging, and the highly hetero-
geneous nature of A oligomer preparations makes conven-
tional competition binding assays difficult to interpret.Wehave
therefore developed a high-throughput screen that utilizes site-
specifically fluorescently labeled protein to identify compounds
that bind to PrP and inhibit both A binding and prion propa-
gation. Following a screen of 1,200 approved drugs, we identi-
fied Chicago Sky Blue 6B as the first small molecule PrP ligand
capable of inhibiting A binding, demonstrating the feasibility
of development of drugs to block this interaction. The interac-
tion of Chicago Sky Blue 6B was characterized by isothermal
titration calorimetry, and its ability to inhibit A binding and
reduce prion levels was established in cell-based assays.
Priondiseases are invariably fatal neurodegenerative diseases
for which there is no effective treatment and encompass
Creutzfeldt-Jakob disease in humans, as well as scrapie, bovine
spongiform encephalopathy, and chronic wasting disease in
animals (1). In humans, prion disease can arise sporadically, be
acquired through infection, or be inherited as a result of muta-
tions in the gene coding for the cellular form of the prion pro-
tein (PrP).3 Prion disease is caused by the recruitment of the
normal cellular formof the protein (PrPC) into self-propagating
polymeric forms, often referred to as PrPSc, although multiple
disease-related isoforms occur associated with infectivity and
neurotoxicity (2–5). Although rare, prion diseases have been
the subject of intense study for many years, and much of what
has been learnt of their fundamental molecular processes is
now being applied to other, more common neurodegenerative
diseases that also involve protein misfolding and aggregation
such as Parkinson and Alzheimer disease (AD) (6, 7). Recently,
a more direct connection between prion protein itself and AD
was suggested when PrPC was identified as a receptor for amy-
loid- (A) oligomers, which are considered as key pathogenic
species in AD (8).
Validation of PrPC as a therapeutic target in prion neurode-
generation was demonstrated using conditional knock-out
mouse models where depletion of neuronal PrPC in adult mice
with established neuroinvasive prion infection prevented neu-
ronal loss and clinical onset, and indeed where early neuro-
pathological and behavioral changes were reversed (9, 10). Sim-
ilarly, PrPC has been successfully therapeutically targeted using
monoclonal antibodies, where cell cultures could be cured of
prion infection (11) and treatment of prion-infectedmice could
prevent disease progression (12). That ligands binding to the
folded domain of PrPC and stabilizing its native fold would
block prion propagationwas supported by biophysical data (13)
and a proof of principle study (14).
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PrPC was identified as a receptor for A oligomers in a cell-
based screen and shown to be required for A-induced inhibi-
tion of hippocampal long-term potentiation (8). Both antibod-
ies (8, 15–19) and knock-out mouse models (8, 17, 20, 21) have
also been used to demonstrate the PrP dependence of the inter-
action of A oligomers and its role in synaptic plasticity and
memory. Although the role of PrP as a receptor for A and its
significance in Alzheimer disease were initially controversial
(22–24), considerable data from independent laboratories have
accumulated supporting the association between PrP and A
oligomers (25–30), whereas the earlier discrepancies could be
explained by differences in the preparation of the A oligomers
and the models used (31). A small molecule inhibitor of the
interaction of A with PrP would be of obvious use in further
investigation of the role of PrP in AD pathogenesis and the
relative importance of other putative A oligomer receptors,
which now include leukocyte immunoglobulin-like receptor
LilrB2 (32), EphB2 kinase (33), and immunoglobulin G Fc
receptor II-b (FcRIIb) (34).
Given the severe unmet clinical need in prion diseases, which
are invariably fatal, there has been considerable interest in the
identification of small molecules that bind to PrPC and prevent
its conversion to pathogenic forms as candidate therapeutics
(35, 36). However, despite extensive efforts, there remain few
examples of high-affinity PrPC ligands, and those that have
been reported generally represent poor starting points for a
medicinal chemistry program to deliver a clinical candidate (14,
36). Despite the firm validation of PrPC as a therapeutic target,
the small molecule therapeutics for prion disease that have
been demonstrated to be successful in vivo either target aggre-
gated prion protein (37), a downstream target, or have an
unknown molecular target (38). We therefore sought to
develop an assay capable of screening large numbers of com-
pounds to identify ones that bind to PrPC.
A fluorescence polarization (FP)-based assay to detect ligand
binding was first established using several known biological
ligands for PrP, including A oligomers. Rather than attempt-
ing to directly detect small molecule-induced changes in the FP
signal, we measured the ability of compounds to inhibit the
binding of theA oligomers. This assaywas then used to screen
a small collection of pharmacologically active compounds with
rapid confirmation of binding using an orthologous assay for
A binding in an ELISA format. The binding of the only com-
pound to show robust activity in both assays, Chicago Sky Blue
6B, was then characterized using isothermal titration calorim-
etry (ITC), and its activity in a cellular contextwas confirmedby
measuring the ability of the compound to lower prion levels in
a chronically prion-infected mouse neuroblastoma cell line
(14).
Experimental Procedures
A1–42 and A1–42 with biotin attached to Asp-1 using a
6-carbon linker (bA1–42) were synthesized and purified byDr.
James I. Elliott at Yale University (New Haven, CT). A oligo-
merswere produced as described previously (17) and contained
a mixture of monomer, spherical oligomers, and protofibrils.
Anti-PrP antibodies ICSM35 and ICSM18 were from D-Gen
Ltd. (London,UK). The PrestwickChemical Library compound
collection of 1,200 compoundswas purchased as 10mMstock in
dimethyl sulfoxide (DMSO) fromPrestwickChemical (Illkirch-
Graffenstaden, France). Chicago Sky Blue 6B solid was pur-
chased from Sigma and dissolved in DMSO 24 h prior to use.
Mutations to the wild-type human prion protein (amino
acids 23–231) were generated byQuikChangemutagenesis and
verified by sequencing. Prion protein with an N-terminal hexa-
histidine tag followed by a 23-amino acid linker and a thrombin
cleavage site was expressed in Escherichia coli (39), solubilized
in 6 M guanidine hydrochloride, and purified by affinity chro-
matography on a nickel-nitrilotriacetic acid column prior to
undergoing stepwise oxidation and elution (40). Following elu-
tion, proteinswere dialyzed for 1 h against 10mMTris-HCl, 100
mM sodium phosphate, pH 5.8, prior to being labeled with
IANBD (N-((2-(iodoacetoxy)ethyl)-N-methyl)amino-7-nitro-
benz-2-oxa-1,3-diazole) ester (Invitrogen). A 10 mM stock of
IANBD ester was freshly made in dimethyl formamide and
added to the protein in a 5-fold molar excess. After 1 h, the
solutionwas filtered through a 0.45-m filter and then dialyzed
extensively against 10mMHEPES, pH 6.5. Proteins were stored
in the presence of 20% (v/v) glycerol at80 °C andusedwithout
further purification. Purity of the proteins was confirmed by
SDS-PAGE and MALDI-TOF mass spectrometry, and confor-
mation of the proteins was confirmed by circular dichroism.
Unlabeled proteins for use in ITC and ELISA experiments were
purified as described previously (40), with theN-terminal hexa-
histidine tag being removed by proteolysis with thrombin and
the proteins being purified by ion exchange chromatography
prior to use.
Circular Dichroism—Circular dichroism spectra of NBD-la-
beled proteins were recorded in 10 mM sodium phosphate, pH
6.5, with 2.5 M protein in a 2-mm path length cuvette using a
Jasco 715 spectropolarimeter.
Fluorescence Assay—NBD-labeled proteins with the N-ter-
minal hexahistidine tag were dialyzed extensively against 10
mM HEPES, pH 6.5. After quantification using an 280 nm of
56,667 mol1 cm1, the protein was diluted in FP buffer (10
mM Hepes, 150 mM NaCl, 0.05% (w/v) Pluronic F127, pH 7.5).
To examine the binding of A oligomers and anti-PrP anti-
bodies, 45l of 133 nM labeled protein in FP bufferwas added to
5 l of 5 M anti-PrP antibodies or 10 M A oligomers in a
384-well black plate (Greiner Bio-One, FLUOTRAC 200) in
triplicate. The FP signal was read after 10 min using a Perkin-
Elmer EnVision plate reader (PerkinElmer, Seer Green, UK)
with excitation at 485 nm and emission at 535 nm.
15 Prestwick plates (96-well plates) each containing 80 com-
pounds at 10 mM in 100% DMSO were diluted initially 1/10 in
100% DMSO, and then 1/10 in water. Finally, either 5 l of
compound or 5 l of 10% (v/v) DMSO (negative control) was
transferred to medium binding 384-well black plate. 40 l of
150 nM protein was added to each well using a Multidrop
Combi (Thermo Scientific). The FP signal was read after 10
min. A oligomers (5l) were added to a final concentration of
1 M with respect to starting Amonomer concentration, and
the FP signal was read again after 30 min. The first reading was
subtracted to the second reading, and this value was compared
with the DMSO only value to identify hit compounds.
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Compounds that gave 50% inhibition without a greater
than 3-fold change in total intensity were retested in duplicate
in the fluorescence assay in a 10-point dose-response curve
starting from 100 M, with selected compounds tested in a
15-point dose-response curve, and results were analyzed using
GraphPad Prism 6 (GraphPad Software Inc.).
ELISA Assay—Human PrP was diluted to 1 M in coating
buffer (10 mM sodium carbonate, pH 9.6), incubated overnight
in medium binding 96-well white plates (LUMITRAC 200,
Greiner Bio-One), and blocked for 1 h with Superblock (Pierce,
Cramlington, UK). For direct binding experiments, anti-PrP
antibodies ICSM18 and ICSM35 or biotinylated A oligomers
were added in PBS and incubated for 15 min. After washing,
dissociation-enhanced lanthanide fluorescent immunoassay
(DELFIA) Eu-N1 anti-mouse antibody or DELFIA Eu-N1
streptavidin (PerkinElmer) was added and incubated for 30min
prior to the addition of DELFIA enhancement solution
(PerkinElmer). For inhibition experiments, compounds were
added in PBS supplemented with 1% (v/v) DMSO, 0.05% (v/v)
Tween 20. After 30 min, 100 nM biotinylated A oligomer was
added. Plates were incubated for a further 15 min with gentle
rocking prior to washing and detection with DELFIA Eu-N1
streptavidin. Following the addition of DELFIA enhancement
solution, plates were incubated for 1 h at room temperature,
and time-resolved fluorescence intensity wasmeasuredwith an
EnVision plate readerwith excitation at 320 nm, andwith emis-
sion being measured at 615 nm with a 160-s delay.
Isothermal Titration Calorimetry—Titrations were per-
formed in triplicate at 25 °C on a VP-ITC (MicroCal) device.
After removal of the N-terminal hexahistidine tag, the proteins
were extensively dialyzed into 10 mMHepes, 150 mMNaCl, pH
6.5. In each experiment, 10 M protein (10 mM Hepes, 150 mM
NaCl, 5% (v/v) DMSO, pH 6.5) in the cell was titrated with 14
20-l injections (at 180-s intervals) of Chicago Sky Blue at 500
M. Data were collected and analyzed using a one-site model in
the Origin software (version 7.0) provided by MicroCal.
Cell-based A Binding Assay—Binding of A oligomers to
cells was measured as described previously (8), with COS-7
cells transiently transfectedwith pCMV6 (OriGene) expressing
full-lengthmouse prion protein. PrP expression was confirmed
by immunofluorescence. Twenty-four hours after transfection,
A binding was determined by co-incubation with 500 nM
biotinylated A oligomers with increasing concentrations of
Chicago Sky Blue for 2 h at 22 °C prior to fixing. Cells were
subsequently incubated in PBS for 2 h at 65 °C to inactivate
endogenous alkaline phosphatase, blocked with 3% (v/v) don-
key serum in PBS containing 0.1% (v/v) TritonX-100, and incu-
bated overnight at 4 °C with NeutrAvidin-conjugated alkaline
phosphatase (Thermo Scientific). Cells were washed with PBS
and then with alkaline phosphatase buffer (100 mM Tris-HCl
(pH 9.5), 100mMNaCl, 5mMMgCl2) to remove unboundNeu-
trAvidin-conjugated alkaline phosphatase, prior to staining
with 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetra-
zolium. The number of A-positive cells in eachwell was deter-
mined using a Bioreader 5000-E (Bio-Sys).
Cell-based Anti-prion Assay—Compounds were incubated
for 3 days with N2a cells (PK1 subclone) (41) chronically
infected with RML mouse prions at 37 °C in Opti-MEM plus
penicillin/streptomycin. PrPSc levels were measured in a dot
blot assay following denaturation and digestionwith proteinase
K, with detection using ICSM18 and visualization using a LI-
COR Odyssey reader.
Results
To reduce the potential perturbation of the native protein
structure caused by the introduction of a fluorescent probe, we
first identified six aromatic residues that, by inspection of the
available PrP structures, were surface-exposed (42), and there-
fore most likely to be able to accommodate the fluorophore
without significantly disrupting the native structure of the pro-
tein (Fig. 1). These were then individually mutated to a cysteine
residue to allow labelingwith a thiol-reactive fluorescent probe.
To furtherminimize the disruption of the protein structure, we
also chose to utilize a small (Mr400), environmentally sensi-
tive fluorophore, namely IANBD ester.
The mutant proteins were expressed in E. coli (39) and puri-
fied (40) as described previously prior to being labeled with
IANBD ester. Despite the incorporation of an additional cys-
teine into a protein that already has two cysteine residues, slow
oxidation of the protein encouraged formation of the most
thermodynamically stable disulfide, whereas elution at a rela-
tively lowpHprevented the formation of intermolecular dimers
such that following oxidative refolding on a nickel-nitrilotri-
acetic acid column and labeling with IANBD,  70% of the
protein wasmonomeric as judged by SDS-PAGE in the absence
of reducing agent (Fig. 2A). The absence of large changes in
the conformation of the protein caused by incorporation of the
NBD fluorophore was confirmed by circular dichroism (Fig.
2B). As expected following introduction of an environmentally
sensitive fluorophore, both absorbance and emission spectra
of the different constructs varied considerably (data not
shown). To confirm that the introduction of NBD was not per-
turbing the ability of the proteins to interact with biological
ligands, their binding to a variety of ligandswas determined: A
oligomers, which interact with residues 95–105 (8) and 23–31
(30), and anti-PrP antibodies ICSM18, which binds to residues
143–153 (43), located within the first -helix of the structured
domain of the protein, and ICSM35, which binds to residues
93–105 at the very N terminus of the structured domain (44)
and overlapping the primary A binding site (17). The affinity
FIGURE 1. Representation of the structure of the human prion protein
showing the sites where cysteine residues were introduced to permit
labeling with IANBD.
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of the ligands was determined in an ELISA type assay, and we
found less than 2-fold differences in the affinities of the mutant
protein for the different ligands (Fig. 3).
Because the aim of the study was to develop an assay capable
of screening large compound libraries, we decided to use FP to
monitor ligand-induced changes to the fluorescence of the
probe. This is because changes in the environment of the probe
would be expected to result in a change to its fluorescence life-
time, thereby resulting in a change in the FP signal. This is in
contrast to the majority of FP-based assays where changes to
the FP signal arise from alterations to the mobility of the fluo-
rophore normally caused by a large change in the molecular
weight of the analyte. Using commonly available equipment, it
was possible to read a 384-well plate in the FP assay in 1–2min,
whereas monitoring changes in the fluorescence spectra would
necessitate much lengthier read times and would be more
prone to compound interference.
To identify the optimum construct for screening for PrP
ligands, we tested the ability of the proteins labeled at different
sites to detect the binding of known ligands. All the constructs
demonstrated a statistically significant change in FP signal
upon ligand binding (one-way analysis of variance with Dun-
nett’s multiple comparisons test), although the magnitude of
these changes varied significantly (Fig. 4). Protein labeled at the
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N-terminal residue 31 exhibits changes in fluorescence follow-
ing binding of A oligomers and ICSM35, both of which bind
toward the N terminus of the protein, but not after binding of
ICSM18 to the structured domain. Given the proximity of A
and ICSM35 binding sites to residue 31, it is perhaps unsurpris-
ing that protein labeled at this position is more responsive to
their binding than to ICSM18 binding. Interestingly, despite
being located within the middle of the linear epitope for
ICSM35, protein derivatized at position 99 showed little
response upon ICSM35 binding, although did show changes in
the fluorescence upon A oligomer binding. This suggests that
the environment of the fluorophore is little changed upon
ICSM35 binding, but that binding of A oligomers triggers a
change in the conformation of the protein resulting in a change
in the environment of the fluorophore.
Derivatization of the proteinwithin the structured domain at
positions 145,149, 198, or 218 resulted in a range of sensitivities
to ligand binding. Protein labeled at position 218 was relatively
insensitive to binding of any of the ligands, whereas labeling at
positions 145, 149, or 198 all gave constructs that showed
changes upon A and ICSM18 binding, and much smaller
changes with ICSM35 binding.
We selected the protein labeled at position 145 as being the
most responsive to both A binding and molecules that bind
the structured domain (ICSM18) and then proceeded to use
that protein to screen a small library of 1,200 approved drugs
and pharmacological tool compounds (Prestwick Chemical
Library). In the high-throughput single point screening assay,
the labeled protein was incubated with compounds for 15 min,
and the FP signal was measured to establish whether the com-
pound itself was causing a change in the fluorescence of the
probe. A oligomers were then added, and following a further
30-min incubation, the plate was read again. The initial reading
was subtracted from the reading in the presence of A to give
the FP value, with the 24 compounds that reduced the FP
value by more than 50% being classified as hits. Following the
initial screen, hit compounds were retested in the fluorescence
assay to determine their IC50. Those compounds with an IC50 of
less than 100Mare shown inTable 1, whereas 15 of the initial hit
compounds failed to show any activity in the dose-response assay.
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To exclude the possibility of compounds interfering in the
fluorescence assay and generating false positives, the ability of
the compounds to inhibit the interaction of biotinylated-A
oligomers with unlabeled PrPwas confirmed in an ELISA assay.
The only compound to show reasonable activity in both fluo-
rescence and ELISA assays was Chicago Sky Blue (Table 1 and
Fig. 5).
Because both the ELISA and the fluorescence assays involve
incubating the compound in the presence of PrP and A olig-
omers, it is possible that the compounds are binding to, and
disrupting the A oligomers rather than interacting with PrP.
We therefore used ITC to confirm and further characterize the
nature of the interaction between the compound and PrP.
These experiments showed that Chicago Sky Blue binds the
23–231 construct (Fig. 6A) with a 3:1 ratio with a dissociation
constant of 0.55M 0.04M (n 2.80 0.09,H13.1
0.3 kcal mol1, TS4.6 0.3 kcal mol1). The compound
bindswith similar, but slightly reduced affinity to a shorter con-
struct containing residues 91–231 (Fig. 6B), which still encom-
passes the primary A oligomer binding region of the prion
protein (KD 1.43M 0.24M, n 2.89 0.18,H4.8
0.2 kcal mol1, TS  3.2  0.3 kcal mol1), but shows no
binding to a construct that contains only residues 119–231
(Fig. 6C), suggesting that the Chicago Sky Blue binding site
overlaps that of the A oligomers.
To examine the ability of the Chicago Sky Blue 6B to bind to
PrPwhen expressed in a cellular context, we used thewell char-
acterized PK1 subclone of the mouse neuroblastoma N2a cell
line, which canmaintain a stable long-term infectionwith RML
prions (41). We tested the ability of Chicago Sky Blue to
reduce prion levels in cells that were already chronically
infected with prions. This was measured by the reduction in
the levels of the disease-associated protease-resistant form
of the prion protein PrPSc, following incubation with the
cells for 3 days. Cytotoxicity assays were performed in par-
allel to confirm that this reduction was not the result of a
reduced cell number (14). It is clear that Chicago Sky Blue is
able to reduce prion levels in cells with an IC50 similar to that
observed in the FP assay, without causing significant cyto-
toxicity (Fig. 7A). Finally, we confirmed Chicago Sky Blue’s
ability to inhibit A oligomer binding to cells overexpressing
PrP using transiently transfected COS-7 cells (Fig. 7B), the
system originally used to identify the interaction between
PrP and A oligomers (8).
Discussion
Neurodegenerative diseases such as Alzheimer disease pres-
ent a huge and increasing burden on healthcare systems world-
wide. Despite the increasing prevalence associated with an
aging society, there remains no effective disease-modifying
treatment (45). Similarly, although the numbers affected by
prion disease are far smaller, there is also no effective treatment
for these invariably fatal neurodegenerative diseases. AD,
rather thanbeing a unitary disease entity, is better considered as
a clinicopathological syndrome in which multiple genetic and
environmental factors are involved in both its onset and its
clinical progression. However, amyloid- protein aggregation
is nevertheless considered to be central, and water-soluble,
non-fibrillar, A assemblies are closely linked to memory
impairment (46). The development of disease-modifying treat-
TABLE 1
IC50 values for hits in the fluorescence and ELISA assays
Compound name
Fluorescence assay
IC50 values
ELISA IC50
values
M M
Chicago Sky Blue 6B 0.41 19.7
Verteporfin 1.7 100
Clofazimine 4.4 100
Amphotericin B 5.9 88.8
Benserazide HCl 6.3 100
Anthralin 8.7 100
Propidium iodide 11.2 100
Zafirlukast 15.4 85.7
Alfadolone acetate 31.3 100
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ments for AD remains a challenging but hugely important goal
exemplified by the recent high-profile failures of a number of
clinical trials to meet their primary end point (47). Novel ther-
apeutic strategies are clearly needed, and the identification of
PrP as a receptor for toxic A oligomers provides a tractable
therapeutic approach, and indeed one in which the intense
recent focus on targeting PrP in prion disease has established a
firm experimental foundation (35).
Herewe report the development of a high-throughput screen
capable of identifying drug-like molecules that bind to PrP and
inhibit binding of A oligomers. A significant proportion of the
initial hits (15/24) failed to repeat in the dose-response assay.
This surprisingly high number may reflect the difficulties
inherent in compound and liquid handling for single point
assays within an academic environment, especially when the
assays require multiple additions of reagents. Of the nine com-
pounds that showed activity in the dose-response fluorescence
assay, six showed no inhibition of A binding in the ELISA
assay at concentration up to 100 M. This may reflect the more
stringent nature of the assay and the irreversible nature of the
binding of A oligomers to high density PrP when immobilized
on a solid surface (30), a suggestion supported by the signifi-
cantly higher IC50 values seen for those compounds that did
show activity in the ELISA assay. There is also a good correla-
tion for the affinity of Chicago Sky Blue for PrP measured in
solution as determined by the fluorescence assay (IC50 0.41M)
when compared with a KD of 0.55 M, as determined by ITC.
The utility of the fluorescence assay to screen large numbers of
compounds followed by the ELISA assay to confirm the inter-
action was demonstrated by the observation that the remaining
hit compound, Chicago Sky Blue, interacted not only with
recombinant PrP, but also with PrP in a cellular context: being
able to both reduce prion levels in chronically infected cells
without causing cytotoxicity and inhibit the binding of A olig-
omers to cells overexpressing PrP. Chicago Sky Blue has previ-
ously been shown to inhibit the DNA recombinase Rad51 (48)
and glutamate uptake into synaptic vesicles (49), and is clearly
not suitable for the treatment of either prion or Alzheimer dis-
ease or a promising starting point for a medicinal chemistry
program. It does however represent a useful tool compound for
further dissecting the interaction of A oligomers with PrP in
both cellular and ex vivo models. The fluorescence assay
described is suitable for high-throughput screening of large
chemical libraries, and in conjunction with the ELISA assay to
rapidly identify false positives, could enable the identification of
more promising lead compounds. The use of small, conforma-
tionally sensitive fluorescent probes to screen for ligand bind-
ing may also find wider application especially in the field of
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FIGURE 6. Isothermal titration calorimetry isotherms for the interaction of Chicago Sky Bluewith different length constructs of human prion protein
23–231 (A), 91–231 (B), and 119–231 (C).
FIGURE 7.Activity of Chicago Sky Blue in cell-based assays. A, reduction in
PrPSc in PK1 cells chronically infected with RML prions following 3 days of
treatment with Chicago Sky Blue. conc, concentration. B, inhibition of the
interaction of A oligomers with COS-7 cells overexpressingmouse PrP. Data
are the mean S.E. of four independent experiments. AU, arbitrary units.
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inhibiting protein-protein interactions where there are no
readily accessible enzymatic activities to assay.
It is interesting to note that although ICSM35 and A oligo-
mers bind to a similar region of the protein, they appear to
stimulate different changes to the conformation of the protein,
as judged by the different changes to the FP signal. This sug-
gests that it is unlikely that targeting PrP therapeutically with
antibodies will elicit the same, neurotoxic response as A oli-
gomer binding, a finding supported by recent in vivo data (17,
19, 50).
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